Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 185 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Vepdegestrant for previously treated locally advanced or metastatic ER+/HER2– breast cancer	Vepdegestrant (ARV-471;PF-07850327)	Breast cancer	Breast Cancer	2023	View \| Download
Venglustat for treating type 3 Gaucher disease after 1 therapy	Venglustat	Gaucher disease	Endocrine Nutritional and Metabolic Disorders , Genetic Disorders	2023	View \| Download
Venglustat for treating late onset GM2 gangliosidosis, GM1 gangliosidosis and other ultra-rare disease	Venglustat	GM1 gangliosidosis , GM2 gangliosidosis	Endocrine Nutritional and Metabolic Disorders , Genetic Disorders	2023	View \| Download
Venetoclax in combination with azacitidine for myelodysplastic syndrome	Azacitidine (Vidaza; CC-486) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Myelodysplastic syndrome (MDS)	Haematological Cancer and Lymphomas	2023	View \| Download
Vanzacaftor / tezacaftor / deutivacaftor for the treatment of cystic fibrosis	Deutivacaftor , Tezacaftor (VX-661) , Vanzacaftor	Cystic fibrosis	Genetic Disorders , Respiratory System	2023	View \| Download
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children	Ustekinumab (Stelara; CNTO 1275; CNTO-1275)	Crohn's disease	Gastroenterology , Immunology	2023	View \| Download
Upadacitinib for treating giant cell arteritis	Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate)	Giant cell arteritis	Cardiovascular System	2023	View \| Download
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of unresectable locally advanced or metastatic HER2-positive breast cancer	Pertuzumab (Perjeta; R-1273) , Trastuzumab (Herceptin; RG-597) , Tucatinib (ONT-380)	Breast cancer	Breast Cancer	2023	View \| Download
Trastuzumab duocarmazine for third-line treatment of HER2-positive unresectable metastatic breast cancer	Trastuzumab duocarmazine	Breast cancer	Breast Cancer	2023	View \| Download
Trastuzumab deruxtecan neoadjuvant therapy for high-risk HER2-positive early stage breast cancer	Trastuzumab deruxtecan (DS-8201a; Enhertu)	Breast cancer	Breast Cancer	2023	View \| Download